expert

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 45/100

   [Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Expert Recommendation for Standard MRI Protocol]

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the Korean Society of Radiology · 2025-01-24 · Treatments

   The introduction of anti-amyloid therapies for Alzheimer's disease (AD), such as lecanemab (Lequembi ® ), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI.

   • Treatments
   • Brain Scans
   • Side Effects
2. 48/100

   Survey among experts on the future role of tau-PET in clinical practice and trials

   ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) · 2024-10-01 · Drug development

   Our global survey study shows that dementia experts envision an important role for tau-PET in the future, both in clinical practice and in drug trials, beyond current guidelines and practices.

   • Treatments
   • Brain Scans
3. 71/100

   Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

   ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Neurology and therapy · 2023-10-09 · Drug development

   Passive immunotherapy in AD is largely dominated by anti-amyloid antibodies, which are more numerous and more advanced in the pipeline.

   • Treatments
   • Brain Biology
   • Genetics
4. 38/100

   Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts

   ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2020-03-12 · Brain scans and imaging

   Alzheimer's disease (AD) is the most common neurodegenerative disease among the elderly with a progressive decline in cognitive function significantly affecting quality of life.

   • Brain Scans
   • Biomarkers
   • Treatments
5. 36/100

   Is high oral dose L-arginine intake effective in leukoaraiosis? Preliminary data, study protocol and expert's opinion

   ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current aging science · 2013-07-01 · Biomarkers

   Because of its high prevalence in over-65-year-old subjects, we hypothesized that treatment with 6 gr of Larginine, as supplementary dietary option, could be helpful in patients affected by leukoaraiosis to improve the cognitive and gait impairment often observed in these subjects (as demonstrated by the LADIS study).

   • Diagnosis

All topic tags with their study counts